In our cohort, molecular confirmation directly influenced therapeutic decisions: insulin therapy was successfully discontinued in a patient with a GCK mutation after reclassification of the diabetes type, and sulfonylurea therapy was initiated in a patient with a KCNJ11 mutation based on the genetic finding. The gene discussed is INS; the disease is diabetes mellitus.